TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~Recently (\< 52 weeks) hospitalized for ACS.~Exclusion criteria:~* Age \< 40 years.~* ACS event occurring more than 52 weeks prior to randomization visit.~* LDL-C likely to be \<70 mg/dL (\<1.81 mmo/L), and apolipoprotein B (ApoB) \<80 mg/dL (\<0.8 g/L), and non - high-density lipoprotein cholesterol (HDL-C) \<100 mg/dL (\<2.59 mmol/L) with evidence-based medical and dietary management of dyslipidemia.~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (for alirocumab) subcutaneous (SC) injection every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for up to 64 months.
- Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Type: EXPERIMENTAL): Alirocumab 75 mg SC injection Q2W added to stable LMT for up to 64 months. Alirocumab dose up-titrated to 150 mg Q2W from Month 2 when Low-Density Lipoprotein Cholesterol (LDL-C) levels \>=50 mg/dL (1.29 mmol/L) at Month 1; or if up-titration was missed due to unavailability of LDL-C value, it was up-titrated at month 4 based on LDL-C value at Month 2. For participants receiving 150 mg Q2W, alirocumab dose was down-titrated in a blinded manner to 75 mg Q2W if two consecutive values of LDL-C were \<25 mg/dL (0.65 mmol/L). For participants receiving 75 mg Q2W, alirocumab dose was switched to placebo in a blinded manner if two consecutive values of LDL-C were \<15 mg/dL (0.39 mmol/L).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Paired Promotion of Colorectal Cancer and Social Determinants of Health Screening

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Study participants include community health center staff participating in interviews about the implementation of the intervention. Up to four community health center staff members at each of the four community health centers will participate in key informant interviews twice per year. Patients will receive the paired screening intervention as part of their routine care and will not be individually recruited for the study because the intervention is being offered as part of routine care.~Staff Participants~Inclusion Criteria:~* Staff from community health centers who facilitate screening~* Age 18 and older~Exclusion Criteria:~* Have not participated in the implementation of the paired screening intervention

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Paired Screening Intervention (Type: EXPERIMENTAL): None
- Usual Care Control (Type: NO_INTERVENTION): In this stepped wedge design, all sites have a period of being in usual care, and then providing the Paired Screening Intervention. Sites serve as their own controls in this design.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Therapeutic Workplace to Address Poverty and Substance Use

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older~* meet Diagnostic and Statistical Manual (DSM-V) criteria for substance use disorder~* interested in obtaining employment~Exclusion Criteria:~* suicidal or homicidal ideation~* meet Diagnostic and Statistical Manual (DSM-V) criteria for psychotic disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- IPS Plus Abstinence-Contingent Wage Supplement (Type: EXPERIMENTAL): Abstinence-contingent wage supplements are provided for obtaining and maintaining competitive employment.
- Usual Care Control (Type: NO_INTERVENTION): Counseling and referrals to employment and treatment programs.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TMC114-TiDP3-C176 - A Study in Healthy Volunteers Investigating the Bioequivalence Between Two Commercially Available 400-mg Tablets to One New 800-mg Tablet of Darunavir (DRV) in the Presence of Low-dose Ritonavir Under Fed and Fasted Conditions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy based on a medical evaluation including medical history, physical examination, blood tests and electrocardiogram~* Body Mass Index of 18.0 to 30.0 kg/m² and non-smoker or smoking no more than 10 cigarettes, or 2 cigars, or 2 pipes per day for at least 3 months~* Women must be postmenopausal for at least 2 years or be surgically sterile or be not heterosexually active for the duration of the study or have a vasectomized partner~* Men must agree to use a highly effective method of birth control.~Exclusion Criteria:~* Infection with Hepatitis A, B, or C virus~* infection with HIV~* Women who are pregnant or breastfeeding~* History of, or any current medical condition which could impact the safety of the participant in the study~* Previously participated in a multiple-dose study with DRV.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- 001 (Type: EXPERIMENTAL): Darunavir (DRV) 2x400-mg DRV tablet or 800-mg tablet on Day 3
- 002 (Type: EXPERIMENTAL): ritonavir 100-mg once daily on Day 1 to Day 5

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytological documentation of adenocarcinoma of the colon or rectum~* Progression during or within 3 months following the last administration of approved standard therapies. Patients treated with oxaliplatin in an adjuvant setting should have progressed during or within 6 months of completion of adjuvant therapy~* Patients with measurable or non measurable disease~* Eastern Cooperative Oncology Group (ECOG) Performance Status of \</= 1~* Life expectancy of at least 3 months~* Adequate bone marrow, liver and renal function~Exclusion Criteria:~* Unstable/uncontrolled cardiac disease~* History of arterial or venous thrombotic or embolic events~* Symptomatic metastatic brain or meningeal tumors~* Patients with evidence or history of bleeding diathesis~* Interstitial lung disease - Persistent proteinuria \>/= grade 3~* Unresolved toxicity \> grade 1 attributed to any prior therapy/procedure excluding alopecia and oxaliplatin induced neurotoxicity \</= Grade 2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Regorafenib (Stivarga, BAY73-4506)+BSC (Type: EXPERIMENTAL): Participants received Regorafenib 160 mg per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus Best Supportive Care(BSC).
- Placebo+BSC (Type: PLACEBO_COMPARATOR): Participants received matching placebo tablets per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus Best Supportive Care (BSC).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study in Postmenopausal Women to Determine the Lowest Effective Dose for Relief of Moderate to Severe Hot-Flushes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Menopause~* Reporting a minimum of 7 moderate to severe hot flushes per day for at least 1 week (7 consecutive days), or a minimum of 50 moderate to severe hot flushes per week for at least 1 week (7 consecutive days)~Exclusion Criteria:~* Hormonal treatment~* Contraindication to estrogen/progestogen therapy

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: ACTIVE_COMPARATOR): None
- Arm 2 (Type: ACTIVE_COMPARATOR): None
- Arm 3 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female with confirmed diagnosis of CF~* At least 1 allele of the following CFTR gating mutations: G178R, S549N, S549R, G551S, G970R, G1244E, S1251N, S1255P, G1349D~* Percent predicted forced expiratory volume in 1 second (FEV1) greater than or equal to (\>=) 40 percent (%) predicted normal for age, sex, and height~* 6 years of age or older~* Minimum weight of 15 kilogram (kg) at screening~* Females of childbearing potential must not be pregnant~* Willing to comply with contraception requirements~Exclusion Criteria:~* G551D-CFTR mutation on at least 1 allele~* History of any illness or condition that might confound the results of the study or pose an additional risk in administering ivacaftor to the subject~* An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease within 4 weeks before the first dose of study drug~* History of solid organ or hematological transplantation~* History of alcohol, medication or illicit drug abuse within 1 year before the first dose of study drug~* Ongoing participation in another therapeutic clinical study or prior participation in an investigational drug study within 30 days before screening~* Use of inhaled hypertonic saline treatment~* Use of any inhibitors or inducers of cytochrome (CYP) P450 3A~* Evidence of cataract or lens opacity at screening

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1: Ivacaftor First, Then Placebo (Type: EXPERIMENTAL): Ivacaftor 150 milligram (mg) tablet orally twice daily for 8 weeks in treatment period 1 followed by placebo matched to ivacaftor tablet orally twice daily for 8 weeks in treatment period 2. Washout out period of 4 to 8 weeks was maintained between each treatment period.
- Part 1: Placebo First, Then Ivacaftor (Type: EXPERIMENTAL): Placebo matched to ivacaftor tablet orally twice daily for 8 weeks in treatment period 1 followed by ivacaftor 150 mg tablet orally twice daily for 8 weeks in treatment period 2. Washout out period of 4 to 8 weeks was maintained between each treatment period.
- Part 2: Ivacaftor (Type: EXPERIMENTAL): Ivacaftor 150 mg tablet orally twice daily for 16 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All Ages~* Definite diagnosis of Tuberous Sclerosis according to the modified Gomez criteria~* At least one Subependymal Giant Cell Astrocytoma of at least 1 cm in diameter~* Evidence of SEGA worsening as compared to prior MRI scans~* Females of child bearing potential must use birth control~* Written informed consent~Exclusion Criteria:~* SEGA related surgery is likely to be required in the opinion of the investigator~* Recent heart attack, cardiac related chest pain or stroke~* Severely impaired lung function~* Severe liver dysfunction~* Severe kidney dysfunction~* Pregnancy or breast feeding~* Current infection~* History of organ transplant~* Surgery within two months prior to study enrollment~* Prior therapy with a medication in the same class as Everolimus~* Uncontrolled high cholesterol~* Uncontrolled diabetes~* HIV~* Patients with metal implants thus prohibiting MRI evaluations~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Everolimus (Type: EXPERIMENTAL): Everolimus was administered orally at a starting dose of 4.5mg/m\^2 daily and subsequently titrated to attain whole blood trough concentration of 5 to 15 ng/mL. Dose adjustments were permitted based on safety and whole blood trough concentrations.
- Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo administered orally.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravitreal Ranibizumab Combined With Panretinal Photocoagulation in Patients With Proliferative Diabetic Retinopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Naive Proliferative diabetic retinopathy eyes.~* Best Corrected-Visual Acuity at baseline \> 20/320 in the study eye~* Patients with and without diabetic macular edema~* Type II diabetic subjects as defined by the World Health Organization aged ≥ 18 years.~* Women must be using effective contraception~* Ability to provide written informed consent.~* Indication of panretinal photocoagulation in both eyes~Exclusion Criteria:~* Vitreous hemorrhage or pre-retinal hemorrhage~* Eyes with prior scatter (panretinal) or focal/grid photocoagulation, within the previous 6 months~* Atrophy/scarring/fibrosis/ hard exudates involving the center of the macula.~* Cataract~* Any intraocular surgery within 6 months before trial enrollment~* Previous vitrectomy.~* Any of the following underlying systemic diseases:~* History or evidence of severe cardiac disease or previous thrombus-embolic event

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab (Type: EXPERIMENTAL): Ranibizumab 0,05 mg intravitreal injection
- Laser Therapy (Type: ACTIVE_COMPARATOR): Laser Therapy alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with the ability to understand the requirements of the trial, provide written informed consent, and comply with the trial protocol procedures.~2. Male or female patients aged ≥ 18 years.~3. Diagnosis of MG with generalized muscle weakness meeting the clinical criteria for diagnosis of MG as defined by the Myasthenia Gravis Foundation of America (MGFA) class II, III, IVa and IVb.~Other, more specific inclusion criteria are defined in the protocol~Exclusion Criteria:~1. Pregnant and lactating women, and those intending to become pregnant during the trial or within 90 days after the last dosing.~2. Male patients who are sexually active and do not intend to use effective methods of contraception during the trial or within 90 days after the last dosing or male patients who plan to donate sperm during the trial or within 90 days after the last dosing.~3. MGFA Class I and V patients.~4. Patients with worsening muscle weakness secondary to concurrent infections or medications.~5. Patients with known seropositivity or who test positive for an active viral infection at Screening with:~   * Hepatitis B Virus (HBV) (except patients who are seropositive because of HBV vaccination)~  * Hepatitis C Virus (HCV)~  * Human Immunodeficiency Virus (HIV)~Other, more specific exclusion criteria are further defined in the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ARGX-113 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bupropion Treatment for Youth Smoking Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 14 to 17 years of age~* Smoked at least 6 cigarettes per day~* Exhaled CO greater than or equal to 10 ppm~* Made at least two previous quit attempts~* Weighed at least 90 pounds~* Able to read English at least the 6th grade level~* Motivated to quit smoking as evidenced by willingness to commit to study protocol requirements for the duration of the study~* provided active parental consent and youth assent~Exclusion Criteria:~* Current use of tobacco products other than cigarettes, unless willing to abstain from these products for the study duration~* Current use of other treatments for smoking cessation~* History or current diagnosis of panic disorder, psychosis, bipolar disorder, or eating disorder~* History of abuse or dependence on alcohol or other recreational or prescription drugs in the three months preceding the study~* Current evidence of clinical depression or Attention Deficit/Hyperactivity Disorder~* Use of any psychoactive drug and/or any type of antidepressant with in four weeks of the treatment phase of the study~* Predisposition to seizure or tic disorders or a personal history of a seizure disorder, family history of seizure disorders, or treatment with medication or therapies that increase the risk of seizures~* Significant history of or current clinical evidence of cardiovascular disease~* (Females)Pregnancy (urine pregnancy test), lactation or, if sexually active, unwillingness to use a medically acceptable form of contraception for the duration of the study~* Only one member of a household was allowed to participate in the study concurrently.

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female subjects \>/= 18 years of age~* History of Heavy uterine bleeding~* Hgb \</= 11~* Practicing acceptable birth control~* Demonstrate ability to understand and comply with protocol~Exclusion Criteria:~* Known Hypersensitivity to oral or IV iron~* Anemia other than iron deficiency anemia~* Iron storage disorders~* Initiation of treatment that may effect degree of heavy uterine bleeding~* Anticipated need for surgery~* Severe psychiatric disorder~* Active infection~* Positive Pregnancy test~* Known Hep B or C or Active Hepatitis~* Received investigational Drug within 30 days~* Alcohol or drug abuse

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ferric Carboxymaltose (FCM) (Type: EXPERIMENTAL): Maximum of 1,000 mg of iron as IV FCM given at weekly intervals until the individual's calculated cumulative dose has been reached or a maximum of 2,500 mg has been administered
- Ferrous Sulfate tablets (Type: ACTIVE_COMPARATOR): 325 mg tablets TID on Days 0 through Day 42

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Histologically confirmed adenocarcinoma of prostate~* Ongoing androgen deprivation therapy with a LHRH analogue or antagonist or bilateral orchiectomy~* Progressive metastatic disease~* Adequate bone marrow, hepatic, and renal function~Exclusion Criteria:~* Known metastases in the brain~* History of other malignancy within the previous 5 years~* Known gastrointestinal disease or procedure that affects the absorption~* Not able to swallow the study drug

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ODM-201 Phase I (Type: EXPERIMENTAL): None
- ODM-201 Phase II Dose 1 (Type: EXPERIMENTAL): None
- ODM-201 Phase II Dose 2 (Type: EXPERIMENTAL): None
- ODM-201 Phase II Dose 3 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete